Science 37 welcomes Emily Rollins to its Board of Directors

– USA, CA –  Science 37, Inc. (NASDAQ: SNCE), the Operating System for today’s more agile clinical trials, today announced the appointment of Emily Rollins to its Board of Directors.

“We are thrilled to welcome Emily to the Science 37 Board,” commented CEO, David Coman. “She is a renowned accounting expert with years of experience advising companies in various stages of growth from a variety of industries. She also shares our passion for increasing access to clinical research for patients and providers—helping make research more representative and accelerating the development of potentially life-saving treatments. We are truly fortunate to have the opportunity to benefit from her perspectives as a board member.”

Ms. Rollins will also serve as the chairperson for the Audit Committee.

About Emily Rollins

Ms. Rollins, a retired Deloitte audit and assurance partner, brings more than 30 years of expertise as she has guided hundreds of clients—from pre-revenue to $10B+ international public companies—through corporate governance, audit, and reporting processes. She chairs multiple board committees from various industries. As a deeply trusted advisor to executive teams,

“Science 37’s aim to make clinical research more accessible for more people is a shared passion and being a part of the Board of Directors at this pivotal moment is an exciting opportunity for me.” said Emily Rollins. “I look forward to working with the executive team as they look to leverage their operating system to disrupt the traditional clinical trial model and make research more efficient to help speed treatments to market for the people who need them.”

About Science 37

Science 37, Inc.’s mission it to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 Clinical Trial Operating System supports today’s more agile clinical research designs with its full-stack, end-to-end technology platform and specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices. Configurable to enable any study type, the Science 37 OS enables up to 15x faster enrollment, 28% better retention, and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation, and data harmonization.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team